JPMorgan removed Akero Therapeutics from the firm’s Analyst Focus List while keeping an Overweight rating on the shares with a $62 price target. The totality of the SYMMETRY dataset continues to support efruxifermin having a differentiated impact on histology across the spectrum of nonalcoholic steatohepatitis. That said, efruxifermin’s impact on fibrotic reversal in SYMMETRY “is obviously disappointing relative to expectations,” and challenges the prospect of a successful Phase 3 outcomes study in cirrhotic patients as planned going forward, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKRO:
- Akero Therapeutics overreaction creates buying opportunity, says Canaccord
- Morgan Stanley removes Akero as Top Pick, cuts target to $33
- 89bio downgraded to Perform at Oppenheimer on reduced FGF21 confidence
- 89bio price target lowered to $27 from $34 at RBC Capital
- 89bio down 27% after Akero reports NASH trial data